JP Morgan Lowers Rating on UPB to 'Hold'
JP Morgan has downgraded UPB to a 'hold' rating with a price target of $8, a 31.15% upside from the current price.
Key Points
- JP Morgan downgraded UPB to 'hold' with a new price target of $8 on June 12, 2026.
- JP Morgan's $8 price target implies 31.15% upside from Upstream Bio, Inc.'s ($UPB) current $6.10 share price.
- UPB shares are trading around $6.1, with recent insider purchases adding interest.
- FMR LLC increased its UPB stake by 583,361 shares, while Decheng Capital reduced its holdings by 418,210 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 12, 2026, JP Morgan downgraded UPB to a 'hold' rating, setting a new price target of $8. This change comes as UPB shares are trading around $6.1. Analyst Tessa Romero led the downgrade, which suggests a more cautious outlook on the stock.
Other Institutional Activity in UPB
FMR LLC grew its holdings in UPB by 583,361 shares, ending with 8,101,563 shares worth about $72.9 million. Meanwhile, Decheng Capital LLC trimmed its position by 418,210 shares, now holding 2,724,868 shares valued at approximately $24.5 million. BlackRock, Inc. slightly increased its stake by 26,185 shares, reaching a total of 3,370,689 shares valued at $30.3 million.
Upstream Bio, Inc. Stock Down 8.8%
UPB shares are currently trading near $6.1. With the recent analyst downgrade and varying institutional activities, the stock remains a point of interest for investors.
Insider Buying and Selling at Upstream Bio, Inc.
On June 9, 2026, several insiders, including Marcella Ruddy and Daniella Beckman, each purchased 17,096 shares of UPB. These transactions were not part of a pre-planned trading scheme, indicating a potential vote of confidence from the company's leadership.
Analysts Set New Price Targets
On June 12, 2026, JP Morgan downgraded UPB to a 'hold' with an $8 price target. Earlier, on June 3, 2026, HC Wainwright & Co. initiated coverage with a 'buy' rating and a $36 target. Mizuho maintained its 'buy' rating with a $50 target on May 14, 2026.
Bottom Line
JP Morgan's downgrade of UPB to 'hold' with an $8 target reflects a cautious stance on the stock's prospects. Despite this, recent insider purchases and varied institutional activities suggest ongoing interest. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect the current market conditions.
Get Upstream Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UPB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.